Increasing clinically relevant doses of sapanisertib and serabelisib produced both down- and left-shifted growth inhibition curves for carboplatin, paclitaxel, selinexor (selective inhibitor of nuclear export being developed for TP53 wild-type endometrial cancer) and palbociclib (CDK4/6 inhibitor) in endometrial cancer lines (Fig. 3a–d). This evidence concerns the gene TP53 and endometrial cancer.